SC
APLS

Savant Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Savant Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,525
Closed -$1.01M – 1095
2024
Q4 		$1.01M Buy
31,525
+9,407
+43% +$283K 0.01% 652
2024
Q3 		$638K Buy
22,118
+8,520
+63% +$316K 0.01% 779
2024
Q2 		$522K Buy
+13,598
New +$616K 0.01% 783

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Savant Capital's APLS Position: Q1 2025 in Review

Savant Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2025, closing a stake of 31,525 shares — an estimated $1.01M sold.

Savant Capital first reported a position in APLS in Q2 2024 and held it in 3 quarters. The position peaked at $1.01M in Q4 2024. 255 funds tracked by Wall St. Rank hold APLS as of Q1 2025.

  • Savant Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Savant Capital sold 31,525 Apellis Pharmaceuticals shares in Q1 2025, an estimated $1.01M.
  • Savant Capital first reported a position in Apellis Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Savant Capital's Apellis Pharmaceuticals position peaked at $1.01M in Q4 2024.
  • 255 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2025.

Based on Savant Capital's 13F filing for Q1 2025, filed 8 May 2025.